242 related articles for article (PubMed ID: 28668884)
1. Loss of Tyrosine Kinase 2 Does Not Affect the Severity of
Yamaji T; Shide K; Kameda T; Sekine M; Kamiunten A; Hidaka T; Kubuki Y; Shimoda H; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Yamamoto S; Hasuike S; Nagata K; Shimoda K
Anticancer Res; 2017 Jul; 37(7):3841-3847. PubMed ID: 28668884
[TBL] [Abstract][Full Text] [Related]
2. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.
Koppikar P; Bhagwat N; Kilpivaara O; Manshouri T; Adli M; Hricik T; Liu F; Saunders LM; Mullally A; Abdel-Wahab O; Leung L; Weinstein A; Marubayashi S; Goel A; Gönen M; Estrov Z; Ebert BL; Chiosis G; Nimer SD; Bernstein BE; Verstovsek S; Levine RL
Nature; 2012 Sep; 489(7414):155-9. PubMed ID: 22820254
[TBL] [Abstract][Full Text] [Related]
3. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
4. JAK-mutant myeloproliferative neoplasms.
Levine RL
Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
[TBL] [Abstract][Full Text] [Related]
5. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
6. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
Stivala S; Codilupi T; Brkic S; Baerenwaldt A; Ghosh N; Hao-Shen H; Dirnhofer S; Dettmer MS; Simillion C; Kaufmann BA; Chiu S; Keller M; Kleppe M; Hilpert M; Buser AS; Passweg JR; Radimerski T; Skoda RC; Levine RL; Meyer SC
J Clin Invest; 2019 Mar; 129(4):1596-1611. PubMed ID: 30730307
[TBL] [Abstract][Full Text] [Related]
7. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.
Tyner JW; Bumm TG; Deininger J; Wood L; Aichberger KJ; Loriaux MM; Druker BJ; Burns CJ; Fantino E; Deininger MW
Blood; 2010 Jun; 115(25):5232-40. PubMed ID: 20385788
[TBL] [Abstract][Full Text] [Related]
8. R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm.
Shide K; Kameda T; Markovtsov V; Shimoda HK; Tonkin E; Fang S; Liu C; Gelman M; Lang W; Romero J; McLaughlin J; Bhamidipati S; Clough J; Low C; Reitsma A; Siu S; Pine P; Park G; Torneros A; Duan M; Singh R; Payan DG; Matsunaga T; Hitoshi Y; Shimoda K
Blood; 2011 Jun; 117(25):6866-75. PubMed ID: 21531978
[TBL] [Abstract][Full Text] [Related]
9. Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.
Bartalucci N; Tozzi L; Bogani C; Martinelli S; Rotunno G; Villeval JL; Vannucchi AM
J Cell Mol Med; 2013 Nov; 17(11):1385-96. PubMed ID: 24237791
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy.
Brkic S; Stivala S; Santopolo A; Szybinski J; Jungius S; Passweg JR; Tsakiris D; Dirnhofer S; Hutter G; Leonards K; Lischer HEL; Dettmer MS; Neel BG; Levine RL; Meyer SC
Leukemia; 2021 Oct; 35(10):2875-2884. PubMed ID: 34480104
[TBL] [Abstract][Full Text] [Related]
11. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
[TBL] [Abstract][Full Text] [Related]
12. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms.
Takei H; Coelho-Silva JL; Tavares Leal C; Queiroz Arantes Rocha A; Mantello Bianco T; Welner RS; Mishima Y; Kobayashi IS; Mullally A; Lima K; Machado-Neto JA; Kobayashi SS; Lobo de Figueiredo-Pontes L
Cancer Sci; 2022 Feb; 113(2):597-608. PubMed ID: 34808021
[TBL] [Abstract][Full Text] [Related]
13. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
Meyer SC; Keller MD; Chiu S; Koppikar P; Guryanova OA; Rapaport F; Xu K; Manova K; Pankov D; O'Reilly RJ; Kleppe M; McKenney AS; Shih AH; Shank K; Ahn J; Papalexi E; Spitzer B; Socci N; Viale A; Mandon E; Ebel N; Andraos R; Rubert J; Dammassa E; Romanet V; Dölemeyer A; Zender M; Heinlein M; Rampal R; Weinberg RS; Hoffman R; Sellers WR; Hofmann F; Murakami M; Baffert F; Gaul C; Radimerski T; Levine RL
Cancer Cell; 2015 Jul; 28(1):15-28. PubMed ID: 26175413
[TBL] [Abstract][Full Text] [Related]
14. Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.
Schnöder TM; Eberhardt J; Koehler M; Bierhoff HB; Weinert S; Pandey AD; Nimmagadda SC; Wolleschak D; Jöhrens K; Fischer T; Heidel FH
J Cancer Res Clin Oncol; 2017 May; 143(5):807-820. PubMed ID: 28233092
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
[TBL] [Abstract][Full Text] [Related]
16. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
17. The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.
Quintás-Cardama A
Leuk Res; 2013 Apr; 37(4):465-72. PubMed ID: 23313046
[TBL] [Abstract][Full Text] [Related]
18. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC
Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080
[TBL] [Abstract][Full Text] [Related]
19. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
[TBL] [Abstract][Full Text] [Related]
20. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
